Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD ... into preclinical and clinical testing has been ...
Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental ... Dyne’s next disease target is facioscapulohumeral muscular dystrophy (FSHD), another rare muscle ...
Johnny Quintana’s life changed at the age of 19 when he was diagnosed with a rare form of muscular dystrophy called Facioscapulohumeral muscular dystrophy (FSHD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback